Literature DB >> 1689318

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody.

H Sunada1, P Yu, J S Peacock, J Mendelsohn.   

Abstract

To investigate the functional significance of epidermal growth factor (EGF) receptor phosphorylation, experimental systems were explored in which receptor phosphorylation on tyrosine and serine/threonine could be differentially stimulated. Exposure of A431 cells to 20 nM EGF at 37 degrees C results in phosphorylation of serine, threonine, and tyrosine sites on the receptor. Monoclonal antibody (mAb) 225 binds to the EGF receptor with affinity comparable to EGF and competes with the binding of EGF. Exposure of A431 cells to 20 nM EGF in the presence of 300 nM anti-EGF receptor mAb 225 (15-fold excess) selectively activated serine and threonine phosphorylation of the receptor, but not tyrosine phosphorylation. This observation indicates that EGF-mediated receptor phosphorylation on tyrosine and on serine/threonine residues is dissociable. The intracellular fate of the EGF receptor was examined under conditions that produce different phosphorylation states of receptor amino acids. Exposure of A431 cells to EGF decreased the half-life (T1/2) of the receptor from 17.8 h to 5.6 h, with activation of tyrosine, serine, and threonine phosphorylation. Incubation with mAb 225 augmented the degradation rate (T1/2 = 8.5 h) without activation of receptor phosphorylation. Concurrent exposure to EGF (20 nM) and mAb 225 (300 nM) resulted in comparable enhanced degradation (T1/2 = 9.5 h), with increased phosphorylation only on serine and threonine residues. These results suggest that serine/threonine phosphorylation is irrelevant to the augmentation of receptor degradation. Methylamine, an inhibitor of lysosomal function that did not affect phosphorylation of the EGF receptor, completely protected EGF receptors from rapid degradation induced by EGF, but it only slightly altered the rate of EGF receptor degradation elicited by mAb 225 or by EGF plus 15-fold excess mAb 225. In contrast, mAb 455, which binds to the receptor but does not inhibit EGF binding and EGF-induced activation of phosphorylation on tyrosine, serine, and threonine residues, did not influence EGF-induced rapid, methylamine sensitive degradation of EGF receptor. The results suggest that when EGF receptors are internalized under conditions that do not activate the receptor tyrosine kinase, they are sorted into a nonlysosomal pathway that differs from the methylamine-sensitive lysosomal pathway traversed following activation by EGF. The data indicate the possibility of a function for tyrosine kinase activation and tyrosine autophosphorylation in determining the lysosomal intracellular pathway of EGF receptor processing and degradation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689318     DOI: 10.1002/jcp.1041420210

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Authors:  Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis
Journal:  Cancer Chemother Pharmacol       Date:  2019-03-20       Impact factor: 3.333

Review 2.  Type I receptor tyrosine kinases as targets for therapy in breast cancer.

Authors:  J Baselga; J Mendelsohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 3.  Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.

Authors:  Robert B Diasio; Jeanne Fourie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

Review 5.  The epidermal growth factor receptor as a target for therapy in breast carcinoma.

Authors:  J Baselga; J Mendelsohn
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

Review 6.  Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Authors:  S M Huang; P M Harari
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

7.  Responsive Contrast Agents: Synthesis and Characterization of a Tunable Series of pH-Sensitive Near-Infrared Pentamethines.

Authors:  Virginia Wycisk; Katharina Achazi; Paul Hillmann; Ole Hirsch; Christian Kuehne; Jens Dernedde; Rainer Haag; Kai Licha
Journal:  ACS Omega       Date:  2016-11-04

8.  Effects of epidermal growth factor on invasiveness through the extracellular matrix in high- and low-metastatic clones of RCT sarcoma in vitro.

Authors:  K Yudoh; H Matsui; M Kanamori; A Maeda; K Ohmori; H Tsuji
Journal:  Jpn J Cancer Res       Date:  1994-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.